SK bioscience has applied for emergency use approval for Novavax’s updated Covid-19 vaccine.
The flu season is back in full swing, and so is SK bioscience’s production of Korea’s first and only cell-based influenza vaccine.
Hyundai Bioscience said Sunday it will develop a broad-spectrum antiviral drug with the U.S. National Institutes of Health (NIH), a federal agency for conducting and supporting medical research.
SK bioscience will acquire a 6.5 percent stake, or 6.5 million shares, in Novavax, a U.S. vaccine developer.
SK bioscience swung to a loss in the second quarter of 2023 due to weak vaccine sales and contract manufacturing organization (CMO) orders.
SK bioscience has signed a memorandum of understanding (MOU) with Thailand’s Government Pharmaceutical Organization (GPO) to establish vaccine infrastructure in the Southeast Asian country.
SK bioscience and Sanofi completed the Phase II clinical trial for a pneumococcal vaccine that the companies are jointly developing, the Korean pharmaceutical company said Friday.
SK bioscience has signed an agreement with the Australia-based Peter Doherty Institute for Infection and Immunity to cooperate on influenza vaccine development.
SK bioscience’s SKYCovione, Korea’s first domestically developed Covid-19 vaccine, was listed for emergency use by the World Health Organization (WHO).
SKYCovion, Korea’s first homegrown Covid-19 vaccine, was approved for sale by Britain's Medicines and Healthcare Products Regulatory Agency (MHRA), developer SK bioscience said Tuesday.
Korea JoongAng Daily Sitemap